FDA's 2025 Roadmap to Reduce Mandatory Animal Testing for Monoclonal Antibodies via Validated New Approach Methodologies (NAMs) Reflects Regulatory Acceptance, Not Immediate Elimination

FDA announced in April 2025 a roadmap to reduce required animal testing for monoclonal antibodies and selected modalities through validated alternative methods such as organ-on-chip systems and AI-based toxicology models; this is regulatory acceptance where validation supports it

Type

evidence-claim

Domain

methodology

Grade

A

License

CC BY-NC 4.0

card_id

L-026

hallmarks

cluster

methodology

primary_disease_area

longevity_general

evidence_tier

A

evidence_anchor_count

5

intake_round

R23

intake_date

2026-05-26

related_experts

related_biomarkers

related_interventions

related_trials

collection_pages

/research/methodology/nams-regulatory-acceptance,/research/capital-industry/regulatory-landscape

LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source

Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.